Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation
This study demonstrated that discontinuation of pemetrexed maintenance did not compromise the efficacy of the first-line immunochemotherapy of metastatic driver-gene-negative nsqNSCLC, and identified potential biomarkers for decision making of pemetrexed discontinuation.
Authors
- Zhao Xinmin
- Huijie Wang (ORCID: https://orcid.org/0000-0002-1451-5158)
- Zhenhua J. Wu
- Bo Yu
- Chenchen Wei
- Xi Yang
- Xianghua Wu
- Zhihuang Hu
- Hui Yu
- Ke Gong
- Jingjing Wu
- Ying Lin
- Jialei Wang
- Yao Zhang
Institutions
- Fujian Medical University (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.21037/tlcr-2025-aw-1244
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00